Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab is conducting a Phase 1/2 clinical study titled ‘Phase 1/2 Study of PRO1160 in Patients With Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL).’ The study aims to evaluate the safety, tolerability, and effectiveness of GEN1160, a targeted antibody-drug conjugate, in treating these advanced cancers. This research is significant as it explores potential new treatment options for patients with limited alternatives.
The intervention being tested is GEN1160, a biological drug administered via intravenous infusion. It is designed to target CD70, a protein found on the surface of cancer cells, potentially improving treatment outcomes for patients with solid tumors and blood cancers.
The study follows an interventional design with a single-group assignment. There is no masking involved, meaning all participants and researchers know the treatment being administered. The primary purpose of the study is treatment-focused, aiming to establish the most effective and safe dosage of GEN1160.
The study began on March 15, 2023, and is currently recruiting participants. The last update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This clinical study update could influence Genmab’s stock performance positively if the results demonstrate GEN1160’s effectiveness and safety, potentially leading to increased investor confidence. The study’s progress is also relevant in the context of competitive cancer treatment markets, where new, effective therapies are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.